NCT06540508View on ClinicalTrials.gov

Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma

Enrolling by invitationOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

February 1, 2025

Study Completion Date

May 1, 2025

Conditions
Hepatocellular Carcinoma
Trial Locations (1)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER